IRVING, Texas, Aug. 23
Caris Life Sciences appoints Dave Fredrickson to its Board of Directors. Fredrickson's expertise in global biopharma and precision medicine will drive innovative healthcare solutions. Read more about his role and Caris' mission.
Caris Life Sciences, a leader in next-generation AI TechBio and precision medicine, has announced the appointment of Dave Fredrickson to its Board of Directors, effective August 15, 2024. This strategic addition is set to bring valuable insights to the company's mission of revolutionizing healthcare through innovative solutions.
Company Statement
"We are honored to welcome Dave to Caris' Board of Directors," said David Dean Halbert, DSc (h.c.), Chairman, Founder, and CEO of Caris. "Dave's extensive leadership experience in global biopharma and knowledge of precision medicine development will provide a unique perspective to help us deliver on our vision to improve patient outcomes across multiple diseases worldwide."
Dave Fredrickson's Credentials
Dave Fredrickson currently serves as the Executive Vice-President of the Oncology Business Unit at AstraZeneca PLC. His notable career includes:
- Roles at AstraZeneca:
- President of AstraZeneca K.K. Japan
- Vice-President, Specialty Care, AstraZeneca U.S.
- Vice Chairman of the European Federation of Pharmaceutical Industries and Associations in Japan
- Director of the Japan Pharmaceutical Manufacturers Association
- Previous Experience:
- Leadership positions at Roche/Genentech
- Oncology Business Unit Manager in Spain
- Strategy, marketing, and sales roles in the U.S.
- Consultant at Monitor Group, LLC (now Monitor Deloitte Group, LLC)
- Education:
- Bachelor of Arts in Government from Georgetown University, Washington, DC
Vision and Commitment
"Caris is a precision medicine innovator," said Mr. Fredrickson. "By harnessing the convergence of science, technology, and data, Caris is providing patients with actionable information about their disease at a molecular level. I am excited to work with fellow board members and the Caris management team to advance innovative breakthroughs and new technologies to improve patient care."
About Caris Life Sciences
Caris Life Sciences is a next-generation AI TechBio company and pioneer in precision medicine.
The company is committed to revolutionizing healthcare and improving the human condition through:
- Comprehensive Molecular Profiling:
- Whole Exome Sequencing
- Whole Transcriptome Sequencing
- Advanced AI and Machine Learning Algorithms:
These tools create a robust platform for early detection, diagnosis, monitoring, therapy selection, and drug development.
Global Presence
Caris Life Sciences is headquartered in Irving, Texas, with additional offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan, and Basel, Switzerland. The company provides services in the U.S., Europe, Asia, and other international markets through its distributor partners.
For more information, visit CarisLifeSciences.com.
